Replimune Appoints Dr. Hyam I. Levitsky To Board Of Directors
in portfolio news
Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Hyam I. Levitsky, M.D. to the company’s Board as an independent non-executive Director.
“Hy is a leading expert in immuno-oncology with deep experience in developing novel cancer immunotherapies,” said Robert Coffin, Ph.D., co-founder and CEO of Replimune. “We are honored to have him serve on our board as we advance our oncolytic immunotherapies into the clinic.”
Dr. Levitsky is a pioneer in immuno-oncology research with expertise in multiple areas including adoptive T cell therapies, cancer vaccines, and immunomodulatory therapies for the treatment of hematologic malignances and solid tumors. He most recently served as the Executive Vice President of Research and Chief Scientific Officer at Juno Therapeutics, recently acquired by Celgene. Prior to joining Juno, Dr. Levitsky served as Head of Cancer Immunology Experimental Medicine at Roche Pharmaceuticals. Dr. Levitsky serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology, has consulted on a number of industry scientific advisory boards and contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications. Dr. Levitsky also holds several patents. He continues to serve as an adjunct Professor of Oncology, Medicine and Urology at Johns Hopkins University School of Medicine.
“Oncolytic immunotherapy is an exciting area of cancer research that has the potential to allow more patients to benefit from immuno-oncologic approaches,” said Dr. Levitsky. “I look forward to collaborating with one of the most experienced teams in oncolytic immunotherapy to advance Replimune’s proprietary Immulytic™ platform.”